OBI Pharma, Inc.

TPEX:4174 Stock Report

Market Cap: NT$13.1b

OBI Pharma Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Heidi Wang

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure1.5yrs
CEO ownershipn/a
Management average tenure2.8yrs
Board average tenure2.5yrs

Recent management updates

Recent updates

OBI Pharma (GTSM:4174) Shareholders Booked A 69% Gain In The Last Year

Mar 12
OBI Pharma (GTSM:4174) Shareholders Booked A 69% Gain In The Last Year

Here's Why OBI Pharma (GTSM:4174) Can Manage Its Debt Despite Losing Money

Jan 18
Here's Why OBI Pharma (GTSM:4174) Can Manage Its Debt Despite Losing Money

If You Had Bought OBI Pharma's (GTSM:4174) Shares Five Years Ago You Would Be Down 82%

Nov 26
If You Had Bought OBI Pharma's (GTSM:4174) Shares Five Years Ago You Would Be Down 82%

CEO

Heidi Wang

1.5yrs

Tenure

Dr. Heidi Wang, Ph D., is Chief Executive Officer of OBI Pharma, Inc. from June 2023. Dr. Wang joined the OBI Pharma, Inc. in June 2023.She brings a wealth of global executive management, scientific know...

Leadership Team

NamePositionTenureCompensationOwnership
Ming-Tain Lai
Chief Scientific Officer5.3yrsNT$7.73m0.0044%
NT$ 571.7k
Heidi Wang
Chief Executive Officer1.5yrsno datano data
Colin Kao
CFO, Accounting Supervisor & Corporate Governance Supervisor1.8yrsno datano data
Po-Jen Chang
Director of Human Resources & Administration4yrsno datano data
Sharon Lee
Director of Public Affairs8.8yrsno datano data
Kevin P. Poulos
Chief Business Officer of OBI Pharma USA11.9yrsno datano data
Wayne Saville
Chief Medical Officer of OBI Pharma USA2.9yrsno datano data
Dong Xu
Senior Vice President of Biostatistics & Data Management of OBI Pharma USAless than a yearno datano data
Wade Liu
Head of Global Manufacturing & Supply Chainless than a yearno datano data
Chun-Hung Chou
Vice President of Chemical Pharmacy and R&D Office2.7yrsno data0.00044%
NT$ 57.7k

2.8yrs

Average Tenure

Experienced Management: 4174's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ming-Chin Chen
Independent Director2.5yrsNT$340.00kno data
Tamon Tseng
Director8.5yrsNT$25.00kno data
Howard S. Lee
Independent Director3.4yrsNT$660.00kno data
Chin-Ting Chiu
Independent Director2.5yrsNT$340.00kno data
Wan-Fang Ting
Director1.3yrsno datano data
Kung-Yee Liang
Chairmanless than a yearno datano data

2.5yrs

Average Tenure

Experienced Board: 4174's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 10:28
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

OBI Pharma, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pinghan HsiehCapital Securities Corporation
Li-chun ChangJih Sun Securities Investment Consulting Co., Ltd.
Yijun ChenSinoPac Securities Investment Service